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As a result of centuries of human use, lead is
omnipresent in the environment. Commercial
use of this substance continues even though
its toxic effects have been recognized since
ancient times (Nriagu 1983), and more recent
studies report health effects associated with
lower and lower lead doses (Canfield et al.
2003; Glenn et al. 2003; Nash et al. 2003;
Schwartz et al. 2000). Lead is not rapidly
cleared from the body; the biologic residence
time of lead in blood is measured in days,
whereas the biologic residence time of lead in
bone is on the order of years to decades (Hu
et al. 1998). In occupational and general popu-
lation samples, low blood lead levels have been
associated with increased blood pressure and
elevated risk of hypertension, effects that may
be progressive (Cheng et al. 2001; Glenn et al.
2003; Nash et al. 2003); increased circulatory
and cardiovascular mortality (Lustberg and
Silbergeld 2002); and progressive declines in
cognitive function over time, even years after
cessation of occupational exposure (Schwartz
et al. 2000, 2002, in press). One of the key
remaining problems in the research of lead tox-
icity is that the mechanisms for these effects
are not well understood.
Interestingly, homocysteine is also asso-
ciated with cardiovascular disease and cog-
nitive dysfunction (Dufouil et al. 2003;
Homocysteine Collaboration 2002). Homo-
cysteine is an independent risk factor for 
vaso-occlusive disease; elevated levels of homo-
cysteine increase the risk of heart disease, stroke,
and peripheral vascular disease and, perhaps
through vascular mechanisms, cognitive dys-
function (Bautista et al. 2002; Dufouil et al.
2003; Homocysteine Collaboration 2002; Prins
et al. 2002; Ravaglia et al. 2003; Wald et al.
2002). Vascular damage by homocysteine may
occur through impaired vascular endothelial
and smooth muscle cell function (Rodrigo et al.
2003). The mechanisms of this impairment
may involve inhibition of nitric oxide synthe-
sis, increased oxidative stress, proliferation of
vascular smooth muscle cells, and altered elas-
ticity of the vascular wall (Rodrigo et al. 2003).
Despite the similarities in these health
effects, the relation of homocysteine and lead
dose has not been previously examined. Herein,
we report associations of blood lead, tibia lead,
and homocysteine in a population-based study
of persons 50–70 years of age in Baltimore,
Maryland. Participants were selected from the
general population, and most are without occu-
pational lead exposure.
Materials and Methods
Study design. The Baltimore Memory Study,
one of the National Institutes of Health’s
disparities initiative grants, is a multilevel
cohort study of risk factors for cognitive
decline in Baltimore city residents of targeted
neighborhoods. The methods are described
elsewhere (Schwartz et al. 2004). The selected
neighborhoods were chosen to provide areas
with a broad range of socioeconomic status
and large numbers of both whites and African
Americans. A cross-sectional analysis of ﬁrst-
visit data was performed.
Subject selection and recruitment. Sampling
and recruitment have been previously described
(Schwartz et al. 2004). In brief, individual
dwellings in the study area were linked to tele-
phone numbers, and households with tele-
phones were randomly selected for recruitment.
Eligibility was then determined on 2,351 sub-
jects (50–70 years of age, living at selected
household, lived in Baltimore at least 5 years),
and of these subjects, 60.8% were scheduled
for an enrollment visit. Of the 1,403 scheduled
for an appointment, 1,140 (81.3%) were
enrolled and subsequently tested. The study
was approved by the Committee for Human
Research of the Johns Hopkins Bloomberg
School of Public Health. All participants pro-
vided written, informed consent before testing
and were paid $50 for their participation.
Data collection. All data were collected at
the study clinic by trained research assistants. A
structured interview included the following
information: demographics, socioeconomic sta-
tus (household income, household assets, occu-
pational status, and educational attainment),
medical history, smoking and alcohol history,
and lead history. First and second visits were
conducted between May 2001 and September
2002, and October 2002 and February 2004,
respectively. A trained phlebotomist drew
a 10-mL blood specimen into a red-top (no
anticoagulant) tube, which was clotted, cen-
trifuged, and stored at –20°C within 1 hr.
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Lead and homocysteine are both associated with cardiovascular disease and cognitive dysfunction. We
evaluated the relations among blood lead, tibia lead, and homocysteine levels by cross-sectional analysis
of data among subjects in the Baltimore Memory Study, a longitudinal study of 1,140 randomly
selected residents in Baltimore, Maryland, who were 50–70 years of age. Tibia lead was measured by
109Cd K-shell X-ray ﬂuorescence. The subject population had a mean ± SD age of 59.3 ± 5.9 years and
was 66.0% female, 53.9% white, and 41.4% black or African American. Mean ± SD blood lead, tibia
lead, and homocysteine levels were 3.5 ± 2.4 µg/dL, 18.9 ± 12.5 µg/g, and 10.0 ± 4.1 µmol/L, respec-
tively. In unadjusted analysis, blood lead and homocysteine were moderately correlated (Pearson’s
r = 0.27, p < 0.01). After adjustment for age, sex, race/ethnicity, educational level, tobacco and alcohol
consumption, and body mass index using multiple linear regression, results revealed that homocysteine
levels increased 0.35 µmol/L per 1.0 µg/dL increase in blood lead (p < 0.01). The relations of blood
lead with homocysteine levels did not differ in subgroups distinguished by age, sex, or race/ethnicity.
Tibia lead was modestly correlated with blood lead (Pearson’s r = 0.12, p < 0.01) but was not associ-
ated with homocysteine levels. To our knowledge, these are the ﬁrst data to reveal an association
between blood lead and homocysteine. These results suggest that homocysteine could be a mechanism
that underlies the effects of lead on the cardiovascular and central nervous systems, possibly offering
new targets for intervention to prevent the long-term consequences of lead exposure. Key words: blood
lead, cross-sectional study, homocysteine, tibia lead. Environ Health Perspect 113:31–35 (2005).
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Bloomberg School of Public Health and stored
at –70°C. Serum homocysteine was measured
by a commercial laboratory using ﬂuorescence
polarization immunoassay (Abbott AxSYM,
Abbott Park, IL). The coefﬁcients of variation
for the quality control samples for three con-
centration levels were 3.64% (low range),
2.24% (mid range), and 2.32% (high range).
Fasting was not requested of the subjects
because study visits were scheduled at all times
of the day for logistical reasons. The variability
between fasting and nonfasting samples is not
likely to exaggerate the association but instead
would dampen it. Conditions that cause short-
term ﬂuctuations in homocysteine levels, such
as protein intake, are not likely to be related
to whole-blood lead levels. Homocysteine
was measured from a sample obtained at the
first study visit in most subjects; however,
254 subjects provided plasma only at the ﬁrst
visit so had serum obtained at the second visit
for homocysteine measurement. Lead was
measured in the metals laboratory of the
Kennedy Krieger Institute (Baltimore, MD)
from the first study visit whole-blood speci-
men using anodic stripping voltammetry
(Schwartz et al. 2004). Tibia lead concentra-
tion was measured at the second study visit by
109Cd-induced K-shell X-ray fluorescence
using previously reported methods (Todd
2000; Todd and McNeill 1993; Todd et al.
1992, 2000). In this population of older
adults without occupational lead exposure,
tibia lead, which has a biologic residence time
of 25–30 years, should not have changed
appreciably between the first and second
study visits.
Statistical methods. The main objectives of
this analysis were a) to evaluate relations of
blood lead and tibia lead levels with homo-
cysteine, controlling for age, race/ethnicity,
sex, and other potential confounding variables;
and b) to evaluate whether these relations were
modified by age, sex, or race/ethnicity. Of
the 1,140 persons enrolled at the first visit,
78 subjects were missing homocysteine values;
10 were missing blood lead values; 7 missing
information on alcohol consumption; 6 miss-
ing body mass index (BMI); and 1 each was
missing information on education and tobacco
use. A total of 1,022 (89.6%) subjects com-
pleted the second study visit, so 82 partici-
pants were missing tibia lead data. Thus, in
analyses with blood lead and tibia lead, 1,037
and 955 subjects were included, respectively.
Subjects with missing homocysteine data were
not statistically different regarding blood lead,
age, or race/ethnicity. To minimize the inﬂu-
ence of large tibia lead values, tibia lead was log
transformed before use in models. Negative
values for tibia lead were converted to 0.1
before log transformation. Associations with
tibia lead were also examined nonparametri-
cally, using a percentile transformation for
tibia lead; results did not differ from those
using the log-transformed tibia lead and are
not reported.
We used multiple linear regression to
examine the relations of blood lead with
homocysteine levels, controlling for covariates.
Models were ﬁrst constructed including known
homocysteine covariates (e.g., age, sex, and
race/ethnicity); then, other potential con-
founding variables were included in a forward
stepwise fashion. Variables were retained in
the final models if they were associated with
homocysteine levels or signiﬁcantly inﬂuenced
the relation of blood or tibia lead with homo-
cysteine (changed the lead coefﬁcient by more
than 10%). The final model included age,
race/ethnicity, sex, educational level (four cate-
gories based on reported years of education and
information on graduate equivalency diploma,
training for trades, and additional educational
certiﬁcates), alcohol (four categories based on
the number of alcoholic drinks per month,
with a drink being defined as one beer, one
glass of wine, one wine cooler, one cocktail, or
one shot of liquor), smoking (four categories
based on the number of cigarettes smoked per
day), and BMI (kilograms per square meter).
We evaluated effect modiﬁcation by including
cross-product terms in the model (e.g., to eval-
uate effect modification by race/ethnicity, a
cross-product of race/ethnicity and blood lead
was included in the model). All statistical
analyses were performed using Stata version
8.0 (Stata Corporation, College Station, TX).
We checked ﬁnal models for the assumptions
of linear regression and model ﬁt using inﬂu-
ence diagnostic procedures, examination of
residuals, and residual–residual plots.
Results
Study subjects were 66.0% female, 41.4%
non-Hispanic black/African American, and
53.9% non-Hispanic white or white/Native
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Table 1. Demographic characteristics for the inclusive study population and lead quartile subsets, Baltimore Memory Study, 2001–2002.
Blood lead quartile
Total Quartile 1 Quartile 2 Quartile 3 Quartile 4
Characteristic (n = 1,037) (n = 241) (n = 271) (n = 262) (n = 263) p-Valuea
Blood lead level [mean (range) µg/dL] 3.5 (0.1–27.3) 1.1 (0.1–1.9) 2.5 (2.0–3.0) 3.8 (3.1–4.4) 6.5 (4.5–27.3)
Homocysteine [mean ± SD (µmol/L)] 10.0 ± 4.1 9.2 ± 3.4 9.3 ± 3.5 9.7 ± 3.6 11.7 ± 5.1 < 0.001
Age [mean ± SD (years)] 59.3 ± 5.9 59.3 ± 5.9 59.3 ± 5.8 59.0 ± 5.9 59.8 ± 6.2 0.52
Sex (% female) 66.0 83.0 72.3 63.7 46.0 < 0.001
Race/ethnicity (%) 0.73
Non-Hispanic black/African American 41.4 44.4 39.9 38.9 42.6
Non-Hispanic white or white/Native American 53.9 49.4 55.7 56.1 54.0
African American mixed race/ethnicity 2.7 2.9 3.0 3.1 1.9
Asian, Hawaiian, Native American, or other 2.0 3.3 1.4 1.9 1.5
BMI [mean ± SD (kg/m2)] 29.8 ± 6.9 31.5 ± 7.8 30.7 ± 7.2 28.8 ± 6.4 28.3 ± 5.4 < 0.001
Current cigarette use (%) 0.008
None 79.8 85.9 80.8 82.4 70.7
< Half pack per day 5.6 3.7 7.8 3.5 7.2
Half pack to < 1 pack per day 7.6 4.2 5.9 8.0 12.2
≥ 1 pack per day 7.0 6.2 5.5 6.1 9.9
Alcoholic beverage use (%) < 0.001
None 40.6 49.9 43.9 38.5 30.8
< 4 per month 15.1 17.4 15.9 13.4 13.7
4–8 per month 12.8 11.2 15.1 14.5 10.3
> 8 per month 31.5 21.6 25.1 33.6 45.2
Education level (%) 0.9
< High school or trade school 10.2 10.4 9.2 8.4 12.9
Completed high school or trade school 41.7 41.5 43.2 41.2 40.7
Some college or associate degree 5.9 6.2 6.3 6.1 4.9
≥ College degree 42.2 41.9 41.3 44.3 41.5
ap-Value from chi-square test for categorical variables or for continuous variables analysis of variance F-test for linear trend across quartiles.American and had a mean (range) age of 59.3
(49–71) years. The mean ± SD blood lead and
homocysteine levels were 3.5 ± 2.4 µg/dL and
10.0 (4.1) µmol/L, respectively (Table 1).
Subjects had a wide range of educational levels,
smoking habits, and alcohol habits; in unad-
justed analysis, these were differentially associ-
ated with blood lead and homocysteine levels,
evaluated in quartiles (Tables 1 and 2). Using
blood lead and homocysteine as continuous
measures, in unadjusted analysis, these were
moderately correlated, with Pearson’s r = 0.27
(p < 0.01). Blood lead and tibia lead levels were
only modestly correlated [Pearson’s r = 0.11,
for the log transformed data (Figure 1), and
r = 0.12 for the untransformed data; both
p-values < 0.01].
We next used multiple linear regression
to evaluate predictors of homocysteine levels,
controlling for covariates (Table 3, Figure 2).
Controlling for age, sex, race/ethnicity, smok-
ing habits, alcohol habits, and educational
level, the results revealed that an increase of
1.0 µg/dL in blood lead was associated with an
increase of 0.35 µmol/L in homocysteine levels
(Figure 2; in the ﬁgure, but not the regression
model, three large values for blood lead are
removed so that the portion of the plot with the
most data could be better visualized). Because
sex was strongly associated with both homo-
cysteine and lead levels, separate models were
next repeated in men and women (Table 3).
The association was larger in males, with a
1.0-µg/dL increase in blood lead resulting in a
0.43-µmol/L increase in homocysteine, com-
pared with a 0.24-µmol/L increase for females,
but this difference did not achieve statistical
signiﬁcance. Finally, there was no effect modiﬁ-
cation by sex or race/ethnicity on relations on
blood lead and homocysteine levels (data not
shown). Tibia lead was not associated with
homocysteine levels, and addition of tibia lead
to the models with blood lead did not change
model ﬁt or other coefﬁcients.
To evaluate whether time of day influ-
enced homocysteine levels, homocysteine was
grouped in consecutive 2-hr intervals based on
time of phlebotomy. Control for time of day
in the ﬁnal regression model did not apprecia-
bly alter the association of blood lead and
homocysteine levels. Additionally, because the
ﬁrst 254 subjects provided plasma, these sub-
jects had blood redrawn at the second study
visit to obtain serum. There was no difference
in the mean homocysteine levels based on
when the sample was obtained, and associa-
tions of blood lead with homocysteine did not
vary by visit number.
Discussion
To our knowledge, this is the first study
to examine relations of blood lead and tibia
lead with homocysteine levels. We observed a
significant association between blood lead
and homocysteine in an older, community-
dwelling, adult, population-based sample in a
major U.S. urban area after controlling for age,
sex, race/ethnicity, alcohol intake, cigarette
smoking, educational level, and BMI. As previ-
ously observed, sex, age, and smoking a pack
or more per day were predictors of homocys-
teine levels (Jacques et al. 2001). Blood lead
may inﬂuence homocysteine levels at very low
dose levels (Figure 2). Among study subjects,
blood lead levels were generally < 15 µg/dL, as
expected in the general population. The study
thus provides evidence of an association at low
blood lead levels, but we were unable to char-
acterize the association at higher blood lead
levels. Although tibia lead was modestly asso-
ciated with blood lead levels, it was neither a
predictor of homocysteine levels nor a con-
founder of its relation with blood lead. Tibia
lead levels were obtained at the second study
visit. Subjects who did not complete the second
study visit were more likely to be African
American (52.4 vs. 40.4%) and were slightly
younger (58.5 vs. 59.4 years of age) compared
with subjects who completed the visit, but there
was no difference in blood lead levels. We do
not believe these small differences account for
Article | Blood lead and homocysteine
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Figure 1. Crude relation of log10-transformed blood
lead levels and log10-transformed tibia lead levels
for 955 participants in the Baltimore Memory Study.
Dashed line represents a locally weighted smoothing
ﬁt (lowess bandwidth, 0.10) (Cleveland 1979).
Table 2. Demographic characteristics of study subjects by homocysteine quartiles, Baltimore Memory Study, 2001–2002.
Homocysteine quartile
Quartile 1 Quartile 2 Quartile 3 Quartile 4
Characteristic (n = 245) (n = 269) (n = 259) (n = 264) p-Valuea
Homocysteine [mean (range) µmol/L] 6.6 (4.4–7.5) 8.3 (7.6–9.0) 10.0 (9.1–11.2) 15.0 (11.3–48.6)
Blood lead level [mean ± SD (µg/dL)] 2.8 ± 1.6 3.2 ± 2.4 3.7 ± 2.1 4.4 ± 2.8 < 0.001
Age [mean ± SD (years)] 57.9 ± 5.5 59.1 ± 5.8 60.0 ± 6.0 60.3 ± 6.2 < 0.001
Sex (% female) 87.8 69.1 59.5 48.9 < 0.001
Race/ethnicity (%) 0.001
Non-Hispanic black/African American 39.2 36.1 42.9 47.4
Non-Hispanic white or white/Native American 51.8 62.4 53.6 47.3
African American/mixed race/ethnicity 5.7 0.4 2.7 2.3
Asian, Hawaiian, Native American or other 3.3 1.1 0.8 3.0
BMI [mean ± SD (kg/m2)] 29.2 ± 6.6 29.6 ± 7.0 30.2 ± 6.8 30.2 ± 7.0 0.27
Current cigarette use (%) 0.001
None 84.5 85.1 79.1 70.8
< Half pack per day 6.1 4.5 4.2 7.6
Half pack to less than 1 pack per day 5.3 5.6 9.7 9.9
≥ 1 pack per day 4.1 4.8 7.0 11.7
Alcoholic beverage use (%) 0.007
None 44.5 39.0 40.9 38.3
< 4 per month 15.9 15.6 14.7 14.0
4–8 per month 18.0 13.0 12.0 8.7
> 8 per month 21.6 32.4 32.4 39.0
Education level (%) 0.002
< High school or trade school 10.2 7.1 10.4 13.2
Completed high school or trade school 39.6 37.2 40.9 48.9
Some college or associates degree 6.5 3.7 8.1 5.3
≥ College degree 43.7 52.0 40.6 32.6
ap-Value from chi-square for categorical variables or for continuous variables analysis of variance F-test for linear trend across quartiles.the contrasting associations of blood and tibia
lead levels with homocysteine. Tibia lead, a
measure of cortical bone lead, is generally a less
important source of blood lead levels than is
lead in trabecular bone, but is a good estimate
of cumulative lead dose (Hu et al. 1998). The
data suggest that bioavailable lead (i.e., blood
lead) was a more important predictor of homo-
cysteine levels than was cumulative lead dose
(i.e., tibia lead).
Lead and homocysteine are both associated
with an increased risk of cardiovascular disease
and, possibly through vascular system mecha-
nisms, central nervous system disease. In epi-
demiologic studies of central nervous system
disease and cardiovascular outcomes, it is inter-
esting to note that study results for lead parallel
those for homocysteine. For example, in an
occupational cohort of men with previous lead
exposure (on average 18 years prior), the sys-
tolic blood pressure increased on average
0.64 mm Hg (SE = 0.25) for every SD
increase in blood lead at baseline (Glenn et al.
2003). In a recent meta-analysis using data
from 30 prospective or retrospective studies, a
25% lower homocysteine level (~ 3 µmol/L)
was associated with an approximately 11%
[odds ratio (OR) = 0.89; 95% confidence
interval (CI), 0.83–0.96] lower ischemic heart
disease risk and a 19% (OR = 0.81; 95% CI,
0.69–0.95) lower stroke risk (Homocysteine
Collaboration 2002). Another meta-analysis
of 20 prospective studies found that for an
increase in serum homocysteine of 5 µmol/L,
the OR for ischemic heart disease was increased
(OR = 1.32; 95% CI, 1.19–1.45), as was the
OR for stroke (OR = 1.59; 95% CI, 1.29–1.96)
(Wald et al. 2002). Other studies support the
similarities between the cardiovascular effects
of lead and homocysteine (Bautista et al. 2002;
Cheng et al. 2001; Kopp et al. 1988; Moller
and Kristensen 1992; Nash et al. 2003; Pocock
et al. 1988).
Both lead and homocysteine also have
similar associations with central nervous system
outcomes [Agency for Toxic Substances and
Disease Registry (ATSDR) 1999; Balbus-
Kornfeld et al. 1995; Dufouil et al. 2003; Prins
et al. 2002; Ravaglia et al. 2003; Schwartz
et al. 2000, 2001]. There are suggestions that
cognitive function is negatively affected by
elevated levels of either lead or homocysteine.
In a population-based study of 1,077 subjects,
neurobehavioral test outcomes were lower in
the upper quintile of homocysteine levels com-
pared with the lower four quintiles (Prins et al.
2002). The mean ± SD homocysteine level of
this population was 11.5 ± 4.1 µmol/L, with
the medians of the quintiles being 7.57, 9.12,
10.54, 12.47, and 16.34 µmol/L, respectively.
Comparison of the mean adjusted difference
in test scores for subjects in the homocysteine
upper quintile versus lower quintiles (looked
at dichotomously) revealed a decrement in psy-
chomotor speed (–0.26; 95% CI, –0.37–0.14),
memory function (–0.13; 95% CI, –0.27–0.01),
and global cognitive function (–0.20; 95%
CI, –0.30–0.11). In a longitudinal study of
1,241 subjects (61–73 years of age), homo-
cysteine levels > 15 µmol/L conferred 2.8
greater odds (p < 0.05) of cognitive decline
compared with those subjects whose levels
were < 10 µmol/L (mean homocysteine level in
this study was 12.2 µmol/L) (Dufouil et al.
2003). For lead, two recent longitudinal stud-
ies of occupational cohorts with current and/or
past lead exposure were associated with longi-
tudinal decline in cognitive function (Schwartz
et al. 2000, in press). One of the studies con-
sisted of former organolead workers (mean
age, 55.6 years) and used an extensive neuro-
behavioral test battery (Schwartz et al. 2000).
In this study, an increase of 15.7 µg/g of peak
tibia lead (using back-extrapolation, the esti-
mated tibia lead level at the end of employ-
ment in lead) was equivalent in its effects on
annual test decline to 5 more years of age at
baseline for six neurobehavioral tests of verbal
memory and learning, executive abilities, and
manual dexterity. Although blood lead, but
not tibia lead, was associated with homo-
cysteine levels, in this cross-sectional study we
cannot be certain whether this means that
recent lead exposure, mobilization of lead from
bone, or both, are the likely source of lead that
explains the association. With the growing evi-
dence that lead may cause progressive eleva-
tions in blood pressure and declines in
cognitive function over time (Glenn et al.
2003; Schwartz et al. 2000, 2001, in press),
this newly observed association between lead
and homocysteine may offer new possibilities
for preventive intervention.
Several targets that lead could be acting
upon could explain this association. Lead can
interact with proteins, particularly those with
a sulfhydryl group (Goering 1993). An exam-
ple of this occurrence is the inhibition of the
δ-aminolevulinic acid dehydratase (ALAD)
enzyme in the heme-synthesis pathway. ALAD
is an octameric metalloenzyme that contains
zinc in the activated state (Simons 1995). The
active site for zinc binding contains two cys-
teine residues. There is competitive inhibition
between lead and zinc, with the ratio of the
afﬁnity of lead to zinc at the metal-binding site
being about 25:1 for the 1-1 ALAD phenotype
(Simons 1995). Such sulfhydryl binding by lead
could be one mechanism that could account for
the observed lead–homocysteine relation. In
the metabolism of methionine, homocysteine
can be remethylated by two different pathways
or undergo transsulferation to cysteine (Ueland
and Refsum 1989). In the transsulferation
pathway there is a unique heme-containing
enzyme, cystathionine β-synthase, that cataly-
ses a pyridoxal 5´-phosphate–dependent con-
densation of serine and homocysteine to give
cystathionine (Banerjee et al. 2003). Work in
the elucidation of the structure of cysta-
thionine β-synthase has revealed two sulfhydryl
groups contained within the heme-binding site
(Meier et al. 2001). Furthermore, homo-
cysteine itself contains a sulfhydryl group, so if
lead has an afﬁnity for this sulfhydryl group,
the metabolism of homocysteine could be
directly inhibited, leading to an accumulation
of homocysteine.
It has been unclear whether homocysteine
is a causative agent or only a marker of disease.
In 1962, homocystinuria in mentally retarded
children was discovered as an inborn error
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Figure 2. Smoothed plot of residuals of blood lead
and homocysteine levels, controlling for covariates.
Values were adjusted for age, sex, race/ethnicity,
BMI, educational level, and tobacco and alcohol use.
The three data points with blood lead concentrations
> 15 µg/dL have been excluded from the plot (but not
from the regression model) so that the portion of the
plot with the most data could be more clearly visual-
ized. The solid line is predicted linear fit, and the
dashed line is from a locally weighted smoothing ﬁt
(lowess bandwidth, 0.05) (Cleveland 1979).
Table 3. Predictorsa of homocysteine levels in subjects with complete data (n = 1,037), Baltimore Memory
Study, 2001–2002.
Total (n = 1,037) Female (n = 684) Male (n = 353)
β (SE β) p-Value β (SE β) p-Value β (SE β) p-Value
Blood lead (µg/dL) 0.35 (0.05) < 0.001 0.24 (0.07) 0.001 0.43 (0.08) < 0.001
Age (years) 0.09 (0.02) < 0.001 0.14 (0.02) < 0.001 –0.02 (0.04) 0.61
Female –1.46 (0.27) < 0.001 — — — —
BMI (kg/m2) 0.05 (0.02) 0.004 0.05 (0.02) 0.02 0.09 (0.04) 0.03
Current cigarette useb
< Half pack per day 1.01 (0.53) 0.06 0.78 (0.62) 0.20 1.30 (0.96) 0.18
Half pack to < 1 pack per day 1.53 (0.47) 0.001 2.05 (0.56) < 0.001 0.80 (0.84) 0.35
≥ 1 packs per day 2.29 (0.49) < 0.001 2.12 (0.60) < 0.001 2.11 (0.83) 0.01
aAdjusted for variables in table as well as race/ethnicity (four categories), educational level (four categories), and alcohol
consumption (none, < 4 per month, 4–8 per month, > 8 per month). bReference group is subjects with no current use. Article | Blood lead and homocysteine
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of metabolism (Carson and Neill 1962;
Gerritsen et al. 1962). In 1964, cystathionine
β-synthetase deﬁciency was demonstrated as a
cause of this disorder (Mudd et al. 1964). The
natural history of cystathionine β-synthetase
deﬁciency includes a 50% chance of a vascular
event (stroke, myocardial infarction, peripheral
arterial or venous thrombosis) by 30 years of
age (Yap 2003). Recent experimental evidence
suggests homocysteine to be a causal agent.
Experimentation has shown isolated hyper-
homocysteinemia to be atherogenic in cysta-
thionine β-synthetase and apolipoprotein-E
double knock-out mice (Wang et al. 2003).
Additionally, homocysteine has been shown to
stimulate the expression and secretion of bio-
logically active monocyte chemoattractant
protein-1 (MCP-1) and interleukin-8 (IL-8)
in human monocytes (Zeng et al. 2003), two
chemokines that are thought to be important
to the development of atherosclerotic plaques.
In conclusion, blood lead was found to be
associated with homocysteine levels in a large,
general population sample. Although causality
cannot be determined from cross-sectional data,
it is interesting to consider the possibility that
this relation of lead and homocysteine could
explain one of the mechanisms of the inﬂuence
of lead on the central nervous and cardiovascu-
lar systems. Whether lead elevates homocys-
teine through enzyme inhibition, as earlier
suggested, or conversely, whether homocysteine
elevates lead because of intravascular binding
[homocysteine has a structure similar to dimer-
captosuccinic acid (DMSA) and penicillamine,
compounds that are known to bind lead], it is
evident that the association exists at very low
blood lead levels, and if the former mechanism
is operative, supports a biologic effect of lead at
low levels. This knowledge may offer new tar-
gets for prevention of the progressive health
effects of lead.
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